deCODE Initiates Chemical Development Collaboration with SGX
News Jun 15, 2007
deCODE chemistry has initiated a new chemical development service collaboration with SGX Pharmaceuticals. The research performed by deCODE chemistry is aimed at developing and executing a scalable production process for SGX.
Under this collaboration SGX will gain access to deCODE’s platform for chemical development including route optimization, production of toxicology lots, cGMP production of clinical batches, physical form characterization, and all associated analytical method development and validation.
“We are pleased that SGX Pharmaceuticals chose the deCODE chemistry team for their chemical development needs,” said Dr. David Zembower, Vice President of Chemistry at deCODE. “Over the years we have continued to build upon our service platform to provide our valued clients with a rapid, cost-effective transition from selection of development candidates through entry into human clinical trials.”
Research Team Discovers Compound that Stops Cancer From SpreadingNews
Using a mouse model, OHSU physician-scientists lead effort to hone a drug that inhibits cancer cells from spreading to other areas in the body.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
New Speakers from Roche and Imperial College London Announced for SMi’s ADMET EventNews
SMi Group Reports: With less than 4 weeks left until the 13th annual ADMET Conference commences in London, SMi announces two new speakers joining the event.READ MORE